Access to medicines and treatment: latest news

Access to medicines and treatment resources

Access to medicines and treatment features

Access to medicines and treatment news from aidsmap

More news

Access to medicines and treatment news selected from other sources

  • HIV and LGTB NGOs and other concerned actors across Europe call for futher action on pre-exposure prophylaxis

    The European AIDS Treatment Group (EATG), Europe’s network of HIV activists, and  AIDES, a leading French NGO in the fight against AIDS and viral hepatitis, backed by 81 European HIV LGBT civil society organisations and concerned actors, issued an urgent HIV Prevention Manifesto today. We demand that pre-exposure prophylaxis for HIV (PrEP) is made available as soon as possible within the European Union, and that Gilead, the company that makes the PrEP medicine Truvada®, submits an application to the European Medicines Agency (EMA) for a change of indication so that its use to prevent HIV can be approved.

    25 February 2015 | EATG
  • Merck places children's HIV drug in shared non-profit patent pool

    U.S. drugmaker Merck & Co has contributed an HIV medicine for children to an international shared patent pool in a move that should speed the development of cheap pediatric formulations for use in poor countries.

    24 February 2015 | Reuters
  • amfAR Report Examines Controversial Pricing of Hepatitis C Treatment

    The new amfAR report, titled “Hepatitis C and Drug Pricing: The Need for a Better Balance,” urges structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge exorbitant prices for their products, however effective they may be.

    19 February 2015 | amfAR
  • The Drug That Is Bankrupting America

    With a rational U.S. drug pricing system, private investors would expect to earn a reasonable multiple of their R&D for a highly successful drug, perhaps even 5 to 10 times the R&D outlays, in order to reflect the long time horizons and high uncertainties surrounding drug development. Yet at a treatment course of $84,000, the multiple for Sovaldi looks to be around 40 times or more.

    18 February 2015 | Huffington Post
  • Migrant primary care charge proposals shelved... for now...

    Migrant rights campaigners can celebrate this week. It seems that ongoing lobbying has led the Department of Health to kick plans for new primary care charges for migrants into the long grass... Now we need to make sure they don't return in the autumn to haunt us.

    16 February 2015 | Migrants' Rights Network
  • Dept of Health - Charging for primary care de-prioritised and postponed

    At a meeting yesterday with the Visitor and Migrant NHS Cost Recovery Programme, the Department of Health announced that plans to extend and amend charging for visitors and migrants for primary care has been de-prioritised and will be subject to public consultation in autumn 2015.

    13 February 2015 | Migrants Rights Network
  • UNITAID: 2015 Hepatitis C medicines technology and market landscape

    This report takes stock of a rapidly changing market, where new products have the potential to become “blockbusters” almost overnight – but also risk becoming quickly outdated due to superior products entering the market.

    13 February 2015 | UNITAID
  • Activists Claim India's Free HIV/AIDS Program Is In 'Shambles'

    India has run out of critical supplies under its state-run HIV/AIDS program, activists say, leaving tens of thousands of infected patients without access to life-saving drugs. There are also shortages of condoms and needles.

    13 February 2015 | Wall Street Journal
  • Gilead agrees 41,000 euro hep-C drug price for 12 week treatment in Germany

    Drugmaker Gilead has agreed on a price for its hepatitis C drug Sovaldi of 41,000 euros ($46,625) for a 12-week treatment for Germany's statutory medical insurers, the GKV association of Germany's statutory medical insurers said.

    13 February 2015 | Reuters
  • Gilead expects big increase in Europeans treated with hep C drug

    Gilead Sciences Inc said on Tuesday it expects the number of hepatitis C patients treated in Europe with its Sovaldi drug to increase dramatically this year, and that approvals for the newer combination pill, Harvoni, could come quickly.

    11 February 2015 | Reuters
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.